Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of pegylated liposomal doxorubicin and gemcitabine in advanced ovarian carcinoma
2005-005725-64Phase 2Active
- Sponsor
- AOU Città della Salute e della Scienza di Torino
- Start
- Jan 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of doxorubicin and gemcitabine in Malignant Ovarian Tumor, sponsored by AOU Città della Salute e della Scienza di Torino. Primary endpoints: time to progression and treatment response rate. Started Jan 2006; status: active.
02
Drugs
doxorubicingemcitabine
03
Conditions
Malignant Ovarian Tumor
Beyond the preview
Go deeper on 2005-005725-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005725-64.